[go: up one dir, main page]

JP2002505433A - 単一細胞におけるｐＲＢのコンホメーションのフローサイトメトリによる検出 - Google Patents

単一細胞におけるｐＲＢのコンホメーションのフローサイトメトリによる検出

Info

Publication number
JP2002505433A
JP2002505433A JP2000533764A JP2000533764A JP2002505433A JP 2002505433 A JP2002505433 A JP 2002505433A JP 2000533764 A JP2000533764 A JP 2000533764A JP 2000533764 A JP2000533764 A JP 2000533764A JP 2002505433 A JP2002505433 A JP 2002505433A
Authority
JP
Japan
Prior art keywords
prb
cells
antibody
cyclin
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000533764A
Other languages
English (en)
Japanese (ja)
Inventor
ツビッグニュー ダーツィンキーウィッツ，
フランク トラガノス，
グロリア ジュアン，
ステファン グルーンウォルド，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York Medical College
Becton Dickinson and Co
Original Assignee
New York Medical College
Becton Dickinson and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Medical College, Becton Dickinson and Co filed Critical New York Medical College
Publication of JP2002505433A publication Critical patent/JP2002505433A/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4736—Retinoblastoma protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
JP2000533764A 1998-02-25 1999-02-24 単一細胞におけるｐＲＢのコンホメーションのフローサイトメトリによる検出 Pending JP2002505433A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7590898P 1998-02-25 1998-02-25
US60/075,908 1998-02-25
PCT/US1999/004015 WO1999044067A1 (fr) 1998-02-25 1999-02-24 DETECTION PAR CYTOMETRIE DE FLUX DE CONFORMATIONS DE pRB DANS DES CELLULES INDIVIDUELLES

Publications (1)

Publication Number Publication Date
JP2002505433A true JP2002505433A (ja) 2002-02-19

Family

ID=22128695

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000533764A Pending JP2002505433A (ja) 1998-02-25 1999-02-24 単一細胞におけるｐＲＢのコンホメーションのフローサイトメトリによる検出

Country Status (4)

Country Link
EP (1) EP1057036A1 (fr)
JP (1) JP2002505433A (fr)
AU (1) AU3310099A (fr)
WO (1) WO1999044067A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010266460A (ja) * 2002-08-01 2010-11-25 Mtm Laboratories Ag 溶液ベースの診断のための方法
JP2018091790A (ja) * 2016-12-06 2018-06-14 東ソー株式会社 細胞の染色方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381535B2 (en) 2002-07-10 2008-06-03 The Board Of Trustees Of The Leland Stanford Junior Methods and compositions for detecting receptor-ligand interactions in single cells
US7393656B2 (en) 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
DE60233574D1 (de) 2001-07-10 2009-10-15 Univ R Verfahren und zusammensetzungen zum nachweis des aktivierungszustands multipler proteine in einzelzellen
US7695926B2 (en) 2001-07-10 2010-04-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting receptor-ligand interactions in single cells
US8399206B2 (en) 2008-07-10 2013-03-19 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US8227202B2 (en) 2008-07-10 2012-07-24 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US20100215644A1 (en) * 2009-02-25 2010-08-26 Nodality, Inc. A Delaware Corporation Analysis of nodes in cellular pathways
EP3183556B1 (fr) * 2014-08-20 2021-02-17 Bio-rad Laboratories, Inc. Trieuse optofluidique
US11047850B2 (en) 2017-08-31 2021-06-29 Agilent Technologies, Inc. Composition for stabilization of antibody formulations containing PerCP

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223408A (en) * 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010266460A (ja) * 2002-08-01 2010-11-25 Mtm Laboratories Ag 溶液ベースの診断のための方法
JP2013210373A (ja) * 2002-08-01 2013-10-10 Roche Mtm Laboratories Ag 溶液ベースの診断のための方法
JP2018091790A (ja) * 2016-12-06 2018-06-14 東ソー株式会社 細胞の染色方法

Also Published As

Publication number Publication date
EP1057036A1 (fr) 2000-12-06
WO1999044067A1 (fr) 1999-09-02
AU3310099A (en) 1999-09-15

Similar Documents

Publication Publication Date Title
US6821740B2 (en) Flow cytometric methods for the concurrent detection of discrete functional conformations of PRB in single cells
Lo et al. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer
Lee et al. Epithelial-mesenchymal transition in cervical cancer: correlation with tumor progression, epidermal growth factor receptor overexpression, and snail up-regulation
Plesca et al. DNA damage response and apoptosis
LaRue et al. Microenvironmental regulation of proliferation in multicellular spheroids is mediated through differential expression of cyclin-dependent kinase inhibitors
US8722325B2 (en) Genetic changes in ATM and ATR/CHEK1 as prognostic indicators in cancer
JP2002505433A (ja) 単一細胞におけるｐＲＢのコンホメーションのフローサイトメトリによる検出
US7781179B2 (en) Identification and isolation of transitional cell carcinoma stem cells
McClellan et al. mRNA detection in living cells: A next generation cancer stem cell identification technique
Pierce et al. SIX2 effects on Wilms tumor biology
Green et al. Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-β inhibitor
WO2017161182A1 (fr) Localisation sous-cellulaire d'analytes cibles
Schmid et al. Measurement of lymphocyte subset proliferation by three-color immunofluorescence and DNA flow cytometry
US8466123B2 (en) Genetic changes in ATM and ATR/CHEK1 as prognostic indicators in cancer
Majka et al. SDF-1 alone and in co-operation with HGF regulates biology of human cervical carcinoma cells.
Mirakian et al. Methods for detecting apoptosis in thyroid diseases
US7186516B2 (en) Methods of detecting specific cell lysis
Basha et al. Comparative study of classical, colorimetric and immunologic staining methods for the assessment of tumor cell viability
Teitell et al. TCL1 expression and Epstein-Barr virus status in pediatric Burkitt lymphoma
US6696241B2 (en) Measuring esterase activity using fluorescent substrates as a way of evaluating cervical cancer
EP3942297B1 (fr) Procédés et systèmes d'évaluation d'échantillons cellulaires
Sharma et al. A novel immunological model for the study of prostate cancer
Suo et al. Type 1 protein tyrosine kinases in Chinese breast carcinomas: a clinicopathologic study
CA2621789A1 (fr) Dosage immunologique in vitro fonctionnel
Ghebeh et al. Comment on “Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells”

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090209

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090217

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090501